Ameriprise Financial Inc Jounce Therapeutics, Inc. Transaction History

Ameriprise Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $644,259 - $915,470	-107,198 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $762,177 - $1.03 Million	107,198 New	107,198 $895,000
Q2 2021 Aug 16, 2021	SELL	$6.58 - $10.66 $78,960 - $127,920	-12,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $80,760 - $166,440	12,000 New	12,000 $123,000
Q4 2020 Feb 12, 2021	SELL	$6.37 - $10.33 $81,688 - $132,471	-12,824 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $58,733 - $140,422	12,824 New	12,824 $104,000
Q2 2018 Aug 14, 2018	SELL	$7.27 - $21.88 $1.29 Million - $3.88 Million	-177,500 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$13.4 - $28.4 $47,784 - $101,274	-3,566 Reduced 1.97%	177,500 $3.97 Million
Q4 2017 Feb 12, 2018	SELL	$12.52 - $17.82 $39,776 - $56,614	-3,177 Reduced 1.72%	181,066 $2.31 Million
Q3 2017 Nov 07, 2017	BUY	$11.17 - $16.99 $2.06 Million - $3.13 Million	184,243	184,243 $2.87 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.